Inmune Bio (INMB) Profit After Tax (2018 - 2026)

Inmune Bio has reported Profit After Tax for 9 years, with the latest figure at -$5.4 million in Q1 2026.

• Quarterly Profit After Tax rose 44.68% year-over-year to -$5.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$41.6 million (down 1.09% YoY) and the FY2025 annual result came in at -$45.9 million, down 9.15% from the prior year.
• Profit After Tax slipped to -$5.4 million in Q1 2026 per INMB's latest filing, from -$5.3 million in the prior quarter.
• Over five years, Profit After Tax peaked at -$5.3 million in Q4 2025 and troughed at -$24.5 million in Q2 2025.
• A 5-year average of -$8.9 million and a median of -$7.7 million in 2022 frame the typical range for Profit After Tax.
• The widest YoY moves for Profit After Tax: up 47.87% in 2025, down 150.95% in 2025.
• Over 5 years, Profit After Tax stood at -$5.4 million in 2022, then tumbled by 55.18% to -$8.4 million in 2023, then declined by 10.21% to -$9.2 million in 2024, then jumped by 42.89% to -$5.3 million in 2025, then decreased by 2.72% to -$5.4 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$5.4 million, -$5.3 million, and -$6.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.